skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine

Review

(2582) Views  (1124) Full article downloads

Authors: Lindsay Zilliox, James W Russell

Published Date January 2010 Volume 2010:3 Pages 7 - 17
DOI: http://dx.doi.org/10.2147/DMSO.S4719

Lindsay Zilliox1, James W Russell1,2

1Department of Neurology, Neuromuscular Division, The University of Maryland School of Medicine, 2VA Maryland Health Care System, Baltimore, MD, USA

Introduction: Neuropathy is one of the most frequent complications of diabetes. Of all the symptoms associated with diabetic neuropathy, pain has the largest impact on sleep and quality of life. In the past few years further medications have been added to the available therapies for neuropathic pain. One of these medications, duloxetine hydrochloride (duloxetine), is a balanced and potent selective serotonin and norepinephrine reuptake inhibitor.

Methods: Medline was searched from January 2005 to September 2009 using the key words duloxetine and peripheral neuropathy for clinical trials limited to human research published in English and duloxetine and pharmacology in the nervous system.

Results: Duloxetine has been shown to effectively reduce diabetic peripheral neuropathic pain compared to placebo at doses of 60 mg/day and 120 mg/day with minimal to moderate side effects. This effect is seen with minimal effects on glycemic control and without any clinically relevant effects on lipid control, or cardiovascular parameters. In addition, its efficacy and tolerability is comparable to other medications commonly used in the management of neuropathic pain. Furthermore, duloxetine performs favorably both in terms of quality of life and in cost utility analyses.

Discussion and conclusion: This article reviewed the issues related to management of diabetic peripheral neuropathic pain, the pharmacology and rationale for use of duloxetine, efficacy studies, and the safety and tolerability of treatment with duloxetine. Duloxetine is an acceptable initial or alternative treatment for patients with diabetic neuropathic pain.

Keywords: duloxetine, diabetic neuropathy, neuropathic pain








Readers of this article also read:

Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients
Update on duloxetine for the management of stress urinary incontinence
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Duloxetine for the management of fibromyalgia syndrome
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Preferences related to attention-deficit/hyperactivity disorder and its treatment
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio